0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Alopecia Possibly Secondary to Topical Ophthalmic β-Blockers

F. T. Fraunfelder, MD; Sheryl J. Menacker, MD; S. Martha Meyer
JAMA. 1990;263(11):1493-1494. doi:10.1001/jama.1990.03440110055020.
Text Size: A A A
Published online

To the Editor.—  Topical ophthalmic β-blockers are the most commonly used treatment for glaucoma. There are three topical ophthalmic β-blockers available: betaxolol, levobunolol, and timolol. Two of these were among the top 200 most commonly used prescription drugs in 1988. Although these β-adrenergic blocking agents are well tolerated by the majority of patients, side effects account for therapy discontinuance in up to 10% of patients.1 Side effects caused by systemic β-blockers also have been reported secondary to use of topical ophthalmic β-blockers, since therapeutic levels of plasma timolol have been observed 1 hour after receiving topical ophthalmic timolol.2,3 Alopecia has been reported in patients who use oral β-blockers.4-8 This is the first report of alopecia due to use of topical ophthalmic β-blockers.The National Registry of Drug-Induced Ocular Side Effects (Department of Ophthalmology, Oregon Health Sciences University, Portland) has received reports of 56 cases of alopecia in

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();